Rubius Therapeutics Inc logo

RUBY

Rubius Therapeutics Inc

$0.73

Earnings Summary

Revenue
$0Mn
Net Profits
$-52.41Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Rubius Therapeutics Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Rubius Therapeutics Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Rubius Therapeutics Inc’s net profit fell -23.82% since last year same period to $-52.41Mn in the Q1 2022. On a quarterly growth basis, Rubius Therapeutics Inc has generated 4.74% jump in its net profits since last 3-months.

Net Profit Margins:

Rubius Therapeutics Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Rubius Therapeutics Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Rubius Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.53
EPS Estimate Current Year
-0.53

Highlights

EPS Estimate Current Quarter:

Rubius Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.53 - a 8.62% jump from last quarter’s estimates.

EPS Estimate Current Year:

Rubius Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.53.

Key Ratios

Key ratios of the Rubius Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.58
Return on Assets (ROA)
-0.4
Return on Equity (ROE)
-1.12
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Rubius Therapeutics Inc’s earning per share (EPS) fell -13.73% since last year same period to -0.58 in the Q1 2022. This indicates that the Rubius Therapeutics Inc has generated -13.73% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Rubius Therapeutics Inc’s return on assets (ROA) stands at -0.4.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Rubius Therapeutics Inc’s return on equity (ROE) stands at -1.12.

Dividend Per Share (DPS):

Rubius Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
-0.58
-0.58
0%

Company Information

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas.

Organisation
Rubius Therapeutics Inc
Headquarters
Cambridge, Massachusetts, US
Employees
204
Industry
Health Technology
CEO
Pablo Cagnoni